scholarly journals The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
T E A Helal ◽  
N A Radwan ◽  
H A Mahmoud ◽  
A M E Zaki ◽  
N S Ahmed ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Progenitor Cells ◽  
Chronic Hepatitis C ◽  
Response To Therapy ◽  
Hepatic Progenitor Cells ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
The Mean ◽  
Chronic Hcv

Abstract Background Interferon therapy is used as a line of treatment of chronic hepatitis C virus (HCV) in several areas of the world including Egypt. Objective Our aim is to investigate the value of hepatic progenitor cells (HPCs) in predicting response of patients with chronic HCV, genotype 4 to pegylated interferon (PEGIFN) plus ribavirin (RBV) therapy. Methods Pretreatment liver biopsies obtained from 110 patients with chronic HCV, genotype 4 were examined immunohistochemically for HPCs using cytokeratin 19. The mean number of HPCs as ductular reaction (DR) and as isolated progenitor cells (IPCs) was counted in each case. The patients were classified into: those with sustained virological response (SVR) and those who did not achieve SVR. The results were compared between the two groups. Also, the relationships between HPCs and other clinico-pathologic variables were estimated using multivariate analysis. Results The mean number of HPCs was the only independent predictor of therapeutic response, being significantly higher in non-responders (P = 0 for DR and P = 0.03 for IPCs). On the other hand, fibrosis stage and steatosis were the only independent factors which showed a significant direct association with the mean number of HPCs in the form of DR and IPCs (P = 0 for each). Conclusion The number of HPCs provides prognostic information in chronic HCV since it is significantly associated with stage of fibrosis. More importantly, it can be used as a marker to predict response of patients with chronic HCV to PEGIFN plus RBV therapy.

scholarly journals The role of hepatic progenitor cells in predicting response to therapy in Egyptian patients with chronic hepatitis C, genotype 4

2019 ◽  
Vol 19 (1) ◽  
pp. 1411
Author(s):  
Thanaa El A Helal ◽  
Nehal A Radwan ◽  
Heba A Mahmoud ◽  
Ahmed ME Zaki ◽  
Naglaa S Ahmed ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Progenitor Cells ◽  
Chronic Hepatitis C ◽  
Response To Therapy ◽  
Hepatic Progenitor Cells ◽  
Genotype 4 ◽  
Egyptian Patients

Relationship between hepatic progenitor cells and stellate cells in chronic hepatitis C genotype 4

Apmis ◽  
2017 ◽  
Vol 126 (1) ◽  
pp. 14-20 ◽  
Author(s):  
Thanaa El Sayed Ahmed Helal ◽  
Nermine Ahmed Ehsan ◽  
Nehal Ahmed Radwan ◽  
Eman Abdelsameea
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Progenitor Cells ◽  
Chronic Hepatitis C ◽  
Stellate Cells ◽  
Hepatic Progenitor Cells ◽  
Genotype 4

Potential role of hepatic progenitor cells expression in cases of chronic hepatitis C and their relation to response to therapy: a clinicopathologic study

2006 ◽  
Vol 26 (7) ◽  
pp. 817-826 ◽  
Author(s):  
Athanassios C. Tsamandas ◽  
Ioulia Syrokosta ◽  
Konstantinos Thomopoulos ◽  
Vassiliki Zolota ◽  
Dimitra Dimitropoulou ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Progenitor Cells ◽  
Chronic Hepatitis C ◽  
Potential Role ◽  
Response To Therapy ◽  
Hepatic Progenitor Cells ◽  
Clinicopathologic Study

IL28Bpolymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4

2012 ◽  
Vol 20 (1) ◽  
pp. 59-64 ◽  
Author(s):  
N. Antaki ◽  
S. Bibert ◽  
K. Kebbewar ◽  
F. Asaad ◽  
O. Baroudi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Response To Therapy ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Chronic Hepatitis C Patients

scholarly journals The Liver MicroRNA Expression Profiles Associated With Chronic Hepatitis C Virus (HCV) Genotype-4 Infection: A Preliminary Study

2016 ◽  
Vol 16 (4) ◽  
Author(s):  
Nadia Mohamed El-Guendy ◽  
Reham Helwa ◽  
Medhat Salah El-Halawany ◽  
Shimaa Abdel Rahman Ali ◽  
Marwa Tantawy Aly ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Expression Profiles ◽  
Microrna Expression ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Chronic Hepatitis C Virus ◽  
Preliminary Study

Hepatic progenitor cells in children with chronic hepatitis C

2015 ◽  
Vol 27 (5) ◽  
pp. 561-569 ◽  
Author(s):  
Hanaa A. El-Araby ◽  
Nermine A. Ehsan ◽  
Hatem A. Konsowa ◽  
Basma M. Abd-Elaati ◽  
Ahmad M. Sira
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Progenitor Cells ◽  
Chronic Hepatitis C ◽  
Hepatic Progenitor Cells

Ledipasvir/Sofosbuvir versus Daclatasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C Genotype 4 Patients

2020 ◽  
Vol 15 (1) ◽  
pp. 53-60
Author(s):  
Lamiaa N. Abdelaty ◽  
Ahmed A. Elnaggar ◽  
Amira A. Said ◽  
Raghda R.S. Hussein
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Adverse Events ◽  
Chronic Hepatitis C ◽  
Outcome Measure ◽  
Clinical Laboratory ◽  
Hcv Rna ◽  
Genotype 4 ◽  
Main Outcome Measure ◽  
Hcv Genotype

Background: Chronic Hepatitis C (CHC) is a common progressive healthcare challenge that leads to liver cirrhosis, liver failure, and hepatocellular carcinoma. The optimum therapy was a combination of pegylated interferon and ribavirin, which was associated with moderate response and severe side effects. Sofosbuvir revolutionized CHC treatment, especially in combination with other antiviral agents. Objective: The aim of this study was to compare and evaluate the safety and efficacy of sofosbuvir/ daclatasvir versus sofosbuvir/ledipasvir for the treatment of non-cirrhotic naïve patients with chronic Hepatitis C Virus (HCV) genotype 4 infection for 12 weeks. Method: One hundred CHC genotype 4 patients (70 females, 30 males) were recruited from the hepatology clinic at the Beni-Suef general hospital. Patients were randomly allocated into two groups that received a 12 weeks treatment of either sofosbuvir 400 mg/daclatasvir 60 mg or sofosbuvir 400 mg/ledipasvir 90 mg. The sustained virological response 12 weeks post-treatment (SVR12) (HCV RNA < Lower Limit of Quantification (LLOQ)) was determined to evaluate efficacy. The clinical laboratory tests and any reported adverse effects starting from the administration of the first dose till 30 days after the last dose were assessed to evaluate safety. The main outcome measure was the assessment of the safety, efficacy and compliance of sofosbuvir/ daclatasvir versus sofosbuvir/ledipasvir for the treatment of non-cirrhotic naïve CHC genotype 4 patients for 12 weeks. : The main outcome measure was the assessment of the safety, efficacy and compliance of sofosbuvir/ daclatasvir versus sofosbuvir/ledipasvir for the treatment of non-cirrhotic naïve CHC genotype 4 patients for 12 weeks. Results: SVR12 was achieved by 98% and 96% of patients receiving sofosbuvir plus ledipasvir and sofosbuvir plus daclatasvir, respectively. The most common adverse events reported were headache, and fatigue. No patients discontinued treatment due to adverse events. Conclusion: The findings from this study suggest that the 12 weeks treatment regimens of sofosbuvir plus daclatasvir and sofosbuvir plus ledipasvir were both efficacious and well-tolerated in patients with HCV genotype 4 infection. Impact on Practice: In this paper, we report on the most recent approaches in the treatment of Hepatitis C genotype 4 patients in Egypt. This is significant because this article focuses on comparing the efficacy and tolerability of the most commonly used antiviral drugs in Egypt.

scholarly journals IL-28B predicts response to chronic hepatitis C therapy – fine-mapping and replication study in Asian populations

2011 ◽  
Vol 92 (5) ◽  
pp. 1071-1081 ◽  
Author(s):  
Hidenori Ochi ◽  
Toshiro Maekawa ◽  
Hiromi Abe ◽  
Yasufumi Hayashida ◽  
Rikita Nakano ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Fine Mapping ◽  
Odds Ratio ◽  
Intermediate Frequency ◽  
Response To Therapy ◽  
Type I ◽  
Hcv Genotype ◽  
A Genome

Type I interferon (IFN) is used for the treatment of chronic hepatitis C virus (HCV) infection. Despite advances in antiviral therapy, a large proportion of patients remain infected following current therapies. Through a genome-wide scan, we found two variants (rs8099917 and rs12979860) in the IL-28B locus that affect the outcome of PEG-IFN and ribavirin combination therapy, consistent with recent studies (P = 6.52×10-8; odds ratio 2.46 and P = 8.63×10-8, odds ratio 2.40, respectively). Significant associations were also observed in the case of IFN monotherapy for HCV genotypes 1b and 2a. With rs8099917, HCV genotype 1b patients had a significantly lower frequency of the favourable genotype (86.6 %) compared with healthy controls (91.7 %), and HCV genotype 2a patients had an intermediate frequency (89.9 %). Similar results were found for rs12979860. Fine-mapping analysis revealed that rs8099917 had the strongest association with treatment outcome and 14 others, including four novel single nucleotide polymorphisms, had comparable associations. Haplotype analysis revealed that none of the haplotypes showed stronger association than any single marker. Early non-responders who could not achieve 2 log viral decline during the first 12 weeks of treatment had higher odds ratios for these two variants. The favourable allele of rs8099917 is also associated with initial viral decline at 2 and 4 weeks following the start of therapy. Multivariate analysis of PEG-IFN and ribavirin-treated patients showed that rs8099917 genotype, viral load, fibrosis and age were significant predictors of response to therapy. Common variation at the IL-28B locus is predictive of various IFN-based therapies for HCV independent of regimen or HCV genotype.

scholarly journals Serum Islet Cell Autoantibodies During Interferon α Treatment in Patients With HCV-Genotype 4 Chronic Hepatitis

2006 ◽  
Vol 13 (1) ◽  
pp. 11-15 ◽  
Author(s):  
Gamal Badra ◽  
Imam Waked ◽  
Carlo Selmi ◽  
Saleh M. Saleh ◽  
Ahmed El-Shaarawy ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Middle Eastern ◽  
Interferon Α ◽  
Serum Samples ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Ifna Therapy ◽  
Egyptian Patients

Chronic hepatitis C virus (HCV) infection is a leading cause of end-stage liver disease worldwide and HCV genotype 4 (HCV4) is predominant in African and Middle Eastern countries. It is well established that interferon-α (IFNa) treatment for HCV may trigger serum autoantibodies against pancreatic islet cells (ICA) in a subgroup of patients. Available data on the incidence of ICA during IFNa therapy for chronic HCV4 infection are not conclusive. We investigated the appearance of ICA in 40 naïve Egyptian patients (38 males, 32 ± 6 years) with histologically defined chronic HCV4 infection undergoing IFNa treatment at a dose of 9-million U/week for 24 weeks. Serum samples were collected at baseline and following IFNa therapy and ICA were detected using indirect immunofluorescence. Baseline evaluation indicated that 2/40 (5%) patients had detectable serum ICA. After the completion of the treatment scheme, 12/38 (32%) previously ICA negative patients became ICA positive; however, no patient developed impaired glucose tolerance (IGT) or diabetes during follow-up. In conclusion, we submit that IFNa treatment for chronic hepatitis C (CHC) may induce serum ICA in one-third of Egyptian patients with HCV4. These autoantibodies, however, do not lead to alterations in glucose metabolism.

scholarly journals Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection

2017 ◽  
Vol 12 (1) ◽  
pp. 12 ◽  
Author(s):  
Hussien Ahmed ◽  
Abdelrahman Ibrahim Abushouk ◽  
Mohamed Gadelkarim ◽  
Arwa Mohamed ◽  
Mohamed Gabr ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virologic Response ◽  
Small Sample ◽  
Genotype 4 ◽  
Hcv Genotype ◽  
Small Sample Sizes ◽  
Peginterferon Alfa ◽  
Virologic Response Rate

<p class="Abstract">Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes. Therefore, we conducted this systematic review to investigate the efficacy of daclatasvir in HCV genotype 4 treatment. A computer literature search of PubMed, Scopus, Embase, Ovid, Web of knowledge, and Cochrane central was conducted. We selected studies comparing daclatasvir plus peginterferon-alfa/ribavirin versus placebo plus peginterferon-alfa/ribavirin in patients with HCV genotype 4 infection.  Pooling data from two randomized controlled trials (n = 154 patients) showed that daclatasvir/peg-interferon/ribavirin treatment achieved a moderate sustained virologic response rate of 76% after 12 weeks and of 79% after 24 weeks. The daclatasvir containing regimen was superior to the placebo containing regimen in terms of virologic response rates after 12 weeks (RR=1.9% CI 1.3 to 2.6) and 24 weeks (RR=1.8% CI 1.3 to 2.5). More effective regimens are needed for HCV genotype 4.</p>

Sign in / Sign up

Export Citation Format

Share Document